Lund, Sweden, 2014-02-10 11:44 CET (GLOBE NEWSWIRE) --
The imaging biomarker BSI is highly interesting in many ways, a fact that became evident during the ASCO 2014 Genitourinary Cancers Symposium in San Francisco. This congress is one of the most important prostate cancer congresses in the world and brings together many scientists and physicians within the area.
The great interest in imaging biomarkers was also shown by the fact that it was selected as one of three hot topics for a round table session, "Quantitative imaging of bone metastases in prostate cancer for prognostication , disease progression and response to treatment".
- The need of new imaging biomarkers within treatment of advanced prostate cancer is great. One area of use is monitoring of patients during treatment. Two studies which were presented on the congress show that BSI is a useful biomarker within this area, says Magnus Aurell, CEO EXINI Diagnostics AB.
Increase in bone scan index during abiraterone treatment in relation to reduced survival in mCRPC patients.
Author: Mariana Reza - Department of Clinical Physiology, Clinical Sciences, Malmo, Lund University. Link
Relationship of bone scan index and progression-free survival after docetaxel treatment for CRPC patients with bone metastases.
Author: Atsushi Mizokami - Kanazawa University Graduate School of Medical Science. Link
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 500 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
